Filing Details
- Accession Number:
- 0000899243-19-030273
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-31 16:05:32
- Reporting Period:
- 2019-12-27
- Accepted Time:
- 2019-12-31 16:05:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1743881 | Bridgebio Pharma Inc. | BBIO | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1257809 | Frank Mccormick | C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301 | Chairman Of Oncology | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-12-27 | 25,531 | $36.37 | 1,335,895 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-27 | 21,656 | $36.85 | 1,314,239 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-27 | 3,500 | $38.09 | 1,310,739 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-27 | 13,705 | $39.27 | 1,297,034 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-27 | 16,858 | $40.13 | 1,280,176 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-27 | 883 | $41.31 | 1,279,293 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-27 | 617 | $42.26 | 1,278,676 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-27 | 100 | $42.93 | 1,278,576 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-30 | 16,250 | $35.74 | 1,262,426 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-30 | 900 | $36.86 | 1,261,526 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.
- Represents the weighted average sale price of the shares sold from $35.68 to $36.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all sales reported in footnotes 2 through 10.
- Represents the weighted average sale price of the shares sold from $36.68 to $37.50 per share.
- Represents the weighted average sale price of the shares sold from $37.72 to $38.71 per share.
- Represents the weighted average sale price of the shares sold from $38.77 to $39.765 per share.
- Represents the weighted average sale price of the shares sold from $39.77 to $40.76 per share.
- Represents the weighted average sale price of the shares sold from $40.77 to $41.76 per share.
- Represents the weighted average sale price of the shares sold from $41.87 to $42.84 per share.
- Represents the weighted average sale price of the shares sold from $35.36 to $36.31 per share.
- Represents the weighted average sale price of the shares sold from $36.5101 to $37.25 per share.
Billionaire Hedge Funds
